

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUIDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family

searching

NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option

NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts

NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents

NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications

NEWS 28 JUN 19 CAS REGISTRY includes selected substances from
web-based collections

NEWS 29 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data

NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records

NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations

NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in

NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:31:10 ON 11 JUL 2008

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:31:22 ON 11 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 10 Jul 2008 (20080710/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s (anti pro-HB-EGF) and antibody

504062 ANTI
11 ANTIS
504069 ANTI
(ANTI OR ANTIS)
91060 PRO
1541 PROS
92570 PRO
(PRO OR PROS)
84457 HB
9694 HBS
87354 HB
(HB OR HBS)
29309 EGF
49 EGFS
29320 EGF
(EGF OR EGFS)
0 ANTI PRO-HB-EGF
(ANTI(W)PRO(W)HB(W)EGF)
332216 ANTIBODY

398187 ANTIBODIES
527656 ANTIBODY
(ANTIBODY OR ANTIBODIES)
L1 0 (ANTI PRO-HB-EGF) AND ANTIBODY

=> s (pro-HB-EGF) and antibody

91060 PRO
1541 PROS
92570 PRO
(PRO OR PROS)
84457 HB
9694 HBS
87354 HB
(HB OR HBS)
29309 EGF
49 EGFS
29320 EGF
(EGF OR EGFS)
30 PRO-HB-EGF
(PRO(W)HB(W)EGF)
332216 ANTIBODY
398187 ANTIBODIES
527656 ANTIBODY
(ANTIBODY OR ANTIBODIES)
L2 6 (PRO-HB-EGF) AND ANTIBODY

=> duplicate remove L2

PROCESSING COMPLETED FOR L2

L3 6 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d L3 bib abs 1-6

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:920630 CAPLUS

DN 147:421898

TI G protein .beta..gamma. subunits augment UVB-induced apoptosis by
stimulating the release of soluble heparin-binding epidermal growth factor
from human keratinocytes

AU Seo, MiRan; Lee, Mi-Jeong; Heo, Jin Hee; Lee, Yun-Il; Kim, Yeni; Kim,
So-Young; Lee, Eun-So; Juhnn, Yong-Sung

CS Department of Biochemistry and Molecular Biology and Cancer Research
Institute, Seoul National University College of Medicine, Seoul, 110-779,
S. Korea

SO Journal of Biological Chemistry (2007), 282(34), 24720-24730

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB UV radiation induces various cellular responses by regulating the activity of many UV-responsive enzymes, including MAPKs. The .beta..gamma. subunit of the heterotrimeric GTP-binding protein (G.beta..gamma.) was found to mediate UV-induced p38 activation via epidermal growth factor receptor (EGFR). However, it is not known how G.beta..gamma. mediates the UVB-induced activation of EGFR, and thus we undertook this study to elucidate the mechanism. Treatment of HaCaT-immortalized human keratinocytes with conditioned medium obtained from UVB-irradiated cells induced the phosphorylations of EGFR, p38, and ERK but not that of JNK. Blockade of heparin-binding EGF-like growth factor (HB-EGF) by neutralizing antibody or CRM197 toxin inhibited the UVB-induced activations of EGFR, p38, and ERK in normal human epidermal keratinocytes and in HaCaT cells. Treatment with HB-EGF also activated EGFR, p38, and ERK. UVB radiation stimulated the processing of pro-HB-EGF and increased the secretion of sol. HB-EGF in medium, which was quantified by immunoblotting and protein staining. In addn., treatment with CRM179 toxin blocked UV-induced apoptosis, but HB-EGF augmented this apoptosis. Moreover, UVB-induced apoptosis was reduced by inhibiting EGFR or p38. The overexpression of G.beta.1.gamma.2 increased EGFR-activating activity and sol. HB-EGF content in conditioned medium, but the sequestration of G.beta..gamma. by the carboxyl terminus of G protein-coupled receptor kinase 2 (GRK2ct) produced the opposite effect. The activation of Src increased UVB-induced, G.beta..gamma.-mediated HB-EGF secretion, but the inhibition of Src blocked that. Overexpression of G.beta..gamma. increased UVB-induced apoptosis, and the overexpression of GRK2ct decreased this apoptosis. We conclude that G.beta..gamma. mediates UVB-induced human keratinocyte apoptosis by augmenting the ectodomain shedding of HB-EGF, which sequentially activates EGFR and p38.

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:217652 CAPLUS

DN 146:399418

TI Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholytaurine-induced proliferation of a human colon cancer cell line

AU Cheng, Kunrong; Xie, Guofeng; Raufman, Jean-Pierre

CS Division of Gastroenterology and Hepatology, VA Maryland Health Care System and Program in Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA

SO Biochemical Pharmacology (2007), 73(7), 1001-1012

CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier B.V.

DT Journal

LA English

AB Prior evidence indicates that bile acids stimulate colon cancer cell proliferation by muscarinic receptor-induced transactivation of epidermal growth factor receptors (EGFR). To explore further the mechanism underlying this action, we tested the hypothesis that bile acids activate a matrix metalloproteinase (MMP) that catalyzes release of an EGFR ligand. Initial studies showed that non-selective MMP inhibitors blocked the actions of deoxycholytaurine (DCT), thereby indicating a role for MMP-catalyzed release of an EGFR ligand. DCT-induced cell proliferation was reduced by increasing concns. of EGFR kinase inhibitors, by antibodies to the ligand binding domain of EGFR, by neutralizing antibodies to heparin binding-EGF-like growth factor (HB-EGF) and by CRM197, an inhibitor of HB-EGF release. These findings and our observations with more selective MMP inhibitors suggested that MMP-7, an enzyme known to release HB-EGF, plays a key role in mediating bile acid-induced H508 colon cancer cell proliferation. We obsd. that recombinant HB-EGF and MMP-7 mimicked both the signaling and proliferative actions of bile acids. Strikingly, reducing MMP-7 expression with either neutralizing antibody or small interfering RNA attenuated the actions of DCT. MMP-7 expression in H508 cells was confirmed using quant. reverse transcription PCR. DCT stimulated a greater than 10-fold increase in MMP-7 gene transcription. Co-localization of pro-MMP-7 and pro-HB-EGF at the cell surface (immunofluorescence microscopy) was demonstrated, indicating proximity of the enzyme to its substrate. These findings provide strong evidence that in H508 human colon cancer cells, DCT-induced transactivation of EGFR is mediated by MMP-7-catalyzed release of the EGFR ligand HB-EGF.

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:925223 CAPLUS

DN 142:1315

TI Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle

AU Zhang, Hua; Chalothorn, Dan; Jackson, Leslie F.; Lee, David C.; Faber, James E.

CS Departments of Cell and Molecular Physiology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA

SO Circulation Research (2004), 95(10), 989-997

CODEN: CIRUAL; ISSN: 0009-7330

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB Stimulation of α_1 -adrenoceptors induces proliferation of vascular smooth muscle cells (SMCs) and contributes to arterial remodeling. Although activation of NAD(P)H oxidase and generation of reactive oxygen species (ROS) are required, little is known about this pathway. In this study, the authors examined the hypothesis that epidermal growth factor receptor (EGFR) transactivation and extracellular regulated kinases (ERK) are involved in α_1 -adrenoceptor-mediated SMC growth. Phenylephrine increased protein synthesis in association with a rapid (15 min) and sustained (60 min) doubling of phosphorylation of EGFR and ERK1/2, but not p38 or JNK in the media of rat aorta maintained in organ culture. Antagonists of EGFR phosphotyrosine activity (AG-1478) and ERK phosphorylation (PD-98059, U-0126) abolished phenylephrine-induced protein synthesis, whereas antagonists of p38 or JNK phosphorylation had no specific effect. A competitive antagonist (P22) for heparin binding EGF-like growth factor (HB-EGF) blocked phenylephrine-induced protein synthesis, as did downregulation of pro-HB-EGF (CRM197). Phenylephrine-induced protein synthesis was inhibited by neutralizing antibody to HB-EGF and absent in HB-EGF^{-/-} SMCs. Inhibitors of metalloproteinases (BiPS, KB-R7785) also blocked adrenergic growth. The neutralizing antibody against HB-EGF had no effect on the two-fold increase in ROS generation induced by phenylephrine (DCF fluorescence), suggesting that stimulation of NAD(P)H oxidase by α_1 -adrenoceptor occupation precedes HB-EGF release. Cell culture studies confirmed and extended these findings. These data suggest that α_1 -adrenoceptor-mediated SMC growth requires ROS-dependent shedding of HB-EGF, transactivation of EGFR, and activation of the MEK1/2-dependent MAP kinase pathway. This trophic pathway may link sympathetic activity to arterial wall growth in adaptive remodeling and hypertrophic disease.

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:389324 CAPLUS

DN 139:115428

TI TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells

AU Gschwind, Andreas; Hart, Stefan; Fischer, Oliver M.; Ullrich, Axel

CS Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, D-82152, Germany

SO EMBO Journal (2003), 22(10), 2411-2421

CODEN: EMJODG; ISSN: 0261-4189

PB Oxford University Press

DT Journal

LA English

AB Communication between G protein-coupled receptor (GPCR) and epidermal

growth factor receptor (EGFR) signaling systems involves cell surface proteolysis of EGF-like precursors. The underlying mechanisms of EGFR signal transactivation pathways, however, are largely unknown. We demonstrate that in squamous cell carcinoma cells, stimulation with the GPCR agonists LPA or carbachol specifically results in metalloprotease cleavage and release of amphiregulin (AR). Moreover, AR gene silencing by siRNA or inhibition of AR biol. activity by neutralizing antibodies and heparin prevents GPCR-induced EGFR tyrosine phosphorylation, downstream mitogenic signaling events, cell proliferation, migration and activation of the survival mediator Akt/PKB. Therefore, despite some functional redundancy among EGF family ligands, the present study reveals a distinct and essential role for AR in GPCR-triggered cellular responses. Furthermore, we present evidence that blockade of the metalloprotease-disintegrin tumor necrosis factor- α -converting enzyme (TACE) by the tissue inhibitor of metalloprotease-3, a dominant-neg. TACE mutant or RNA interference suppresses GPCR-stimulated AR release, EGFR activation and downstream events. Thus, TACE can function as an effector of GPCR-mediated signaling and represents a key element of the cellular receptor cross-talk network.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:84701 CAPLUS
 DN 134:126503
 TI Angiotensin AT1 and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation
 AU Fujiyama, Soichiro; Matsubara, Hiroaki; Nozawa, Yoshihisa; Maruyama, Katsuya; Mori, Yasukiyo; Tsutsumi, Yoshiaki; Masaki, Hiroya; Uchiyama, Yoko; Koyama, Yoko; Nose, Atsuko; Iba, Osamu; Tateishi, Eriko; Ogata, Nahoko; Jyo, Nobuo; Higashiyama, Shigeki; Iwasaka, Toshiji
 CS Dep. Medicine II and Ophthalmology, Kansai Medical Univ., Osaka, Japan
 SO Circulation Research (2001), 88(1), 22-29
 CODEN: CIRUAL; ISSN: 0009-7330
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 AB Angiotensin II (Ang II)-mediated signals are transmitted via heparin binding epidermal growth factor (EGF)-like growth factor (HB-EGF) release followed by transactivation of EGF receptor (EGFR). Although Ang II and HB-EGF induce angiogenesis, their link to the angiopoietin (Ang)-Tie2 system remains undefined. We tested the effects of Ang II on Ang1, Ang2, or Tie2 expression in cardiac microvascular endothelial cells expressing

the Ang II receptors AT1 and AT2. Ang II significantly induced Ang2 mRNA accumulations without affecting Ang1 or Tie2 expression, which was inhibited by protein kinase C inhibitors and by intracellular Ca²⁺ chelating agents. Ang II transactivated EGFR via AT1 and inhibition of EGFR abolished the induction of Ang2. Ang II caused processing of pro-HB-EGF in a metalloproteinase-dependent manner to stimulate maturation and release of HB-EGF. Neutralizing anti-HB-EGF antibody blocked EGFR phosphorylation by Ang II. Ang II also upregulated vascular endothelial growth factor (VEGF) expression in an HB-EGF/EGFR-dependent manner. AT2 inhibited AT1-mediated Ang2 expression and phosphorylation of EGFR. In an in vivo corneal assay, AT1 induced angiogenesis in an HB-EGF-dependent manner and enhanced the angiogenic activity of VEGF. Although neither Ang2 nor Ang1 alone induced angiogenesis, sol. Tie2-Fc that binds to angiopoietins attenuated AT1-mediated angiogenesis. These findings suggested that (1) Ang II induces Ang2 and VEGF expression without affecting Ang1 or Tie2 and (2) AT, stimulates processing of pro-HB-EGF by metalloproteinases, and the released HB-EGF transactivates EGFR to induce angiogenesis via the combined effect of Ang2 and VEGF, whereas AT2 attenuates them by blocking EGFR phosphorylation. Thus, Ang II is involved in the VEGF-Ang-Tie2 system via HB-EGF-mediated EGFR transactivation, and this link should be considerable in pathol. conditions in which collateral blood flow is required.

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:522173 CAPLUS

DN 133:217484

TI Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor

AU Kalmes, Andreas; Vesti, Beatrice R.; Daum, Gunter; Abraham, Judith A.; Clowes, Alexander W.

CS Department of Surgery, University of Washington (Seattle), Sunnyvale, CA, USA

SO Circulation Research (2000), 87(2), 92-98

CODEN: CIRUAL; ISSN: 0009-7330

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB Agonists of G protein-coupled receptors, such as thrombin, act in part by transactivating the epidermal growth factor (EGF) receptor (EGFR). Although at first a ligand-independent mechanism for EGFR transactivation was postulated, it has recently been shown that this transactivation by

various G protein-coupled receptor agonists can involve heparin-binding EGF-like growth factor (HB-EGF). Because thrombin stimulation of vascular smooth muscle cell migration is blocked by heparin and because heparin can displace HB-EGF, we investigated the possibility that thrombin stimulation of smooth muscle cells (SMCs) depends on EGFR activation by HB-EGF. In rat SMCs, EGFR phosphorylation and extracellular signal-regulated kinase (ERK) activation in response to thrombin are inhibited not only by the EGFR inhibitor AG1478 and by EGFR blocking antibody but also by heparin and by neutralizing HB-EGF antibody. HB-EGF-dependent signaling induced by thrombin is inhibited by batimastat, which suggests a requirement for pro-HB-EGF shedding by a metalloproteinase. We further demonstrate that this novel pathway is required for the migration of rat and baboon SMCs in response to thrombin. We conclude from these data that the inhibitory effect of heparin on SMC migration induced by thrombin relies, at least in part, on a blockade of HB-EGF-mediated EGFR transactivation.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT